The dengue vaccine market is experiencing significant growth due to the increasing incidence of dengue fever globally. This mosquito-borne viral infection poses a major public health challenge, particularly in tropical and subtropical regions. The market is driven by rising awareness of preventive healthcare and the need for effective vaccination to curb the spread of the disease. Recent developments include the approval and launch of innovative vaccines, such as Dengvaxia and Qdenga, which offer effective protection against multiple dengue virus serotypes. The growing investment in research and development by pharmaceutical companies, alongside government initiatives to promote vaccination campaigns, is expected to further enhance market expansion. As global travel increases and climate change affects mosquito populations, the demand for dengue vaccines is projected to rise, presenting significant opportunities for market players and stakeholders in the healthcare sector.
